Clinical observation of a patient with the Guillain–Barre syndrome after COVID-19 vaccination


DOI: https://dx.doi.org/10.18565/therapy.2021.2.131-137

Roytberg G.E., Dorosh Zh.V., Kondratova N.V., Chudinskaya G.N.

1) N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia, Moscow; 2) AO «Meditsina», Moscow
Abstract. Vaccination is now the most effective method to prevent the spread of highly contagious COVID-19 infection and its complications which is widely used last months all over the world. A clinical observation of 47-year-old patient with clinically confirmed Guillain–Barre syndrome developed 18 days after vaccine Sputnik V injection against COVID-19 infection is presented. Safety of anti-COVID-19 vaccination and identification of risk group are discussed.
Keywords: COVID-19, vaccination, Sputnik V, safety, Guillain–Barre syndrome
Read entire article

Literature


  1. Тельнова Е.А., Щепин В.О., Загоруйченко А.А. Вакцинация как вызов COVID-19. Бюллетень Национального научно-исследовательского института общественного здоровья имени Н.А. Семашко. 2020; 3: 82–89. [Telnova E.A., Shchepin V.O., Zagoruychenko A.A. Vaccination as a challenge COVID-19. Byulleten’ Natsional’nogo nauchno-issledovatel’skogo instituta obshchestvennogo zdorov’ya imeni N.A.Semashko = Bulletin of the National Research Institute of Public Health named after N.A. Semashko. 2020; 3: 82–89 (In Russ.)]. doi: https://dx.doi.org/10.25742/NRIPH.2020.03.010.

  2. Кураков Ф.А., Цветкова Л.А. Оценка перспектив разработки вакцины от коронавирусной инфекции средствами патентного анализа. Менеджер здравоохранения. 2020; 4: 52–57. [Kurakov F.A., Tsvetkova L.A. Assessment of perspectives for COVID-19 vaccines development with patent analysis methods. Menedzher zdravookhraneniya = Healthcare manager. 2020; 4: 52–57 (In Russ.)].

  3. Logunov D.Y., Dolzhikova I.V., Zubcova O.V. et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations two open non-randomized phase 1/2 studies from Russia. Lancet. 2020; 396(10255): 887–97. doi: 10.1016/ S0140-6736(20)31866-3.

  4. Jackson L.A., Anderson E.J., Rouphael N.G. et al. An mRNA vaccine against SARS-CoV-2 – preliminary report. N Engl J Med. 2020; 383(20): 1920–31. doi: 10.1056/NEJMoa2022483.

  5. Синдром Гийена– Барре. Клинические рекомендации. Под общей редакцией Пирадова М.А., Супоневой Н.А., Гришиной Д.А. М.: Горячая линия – Телеком. 2018; 32 с. [Guillain Barre syndrome. Clinical guidelines. Ed. by Piradov M.A., Suponeva N.A., Grishina D.A. Moscow: Goryachaya liniya – Telekom. 2018; 32 p. (In Russ.)].

  6. Mao L., Jin H., Wang M. et al. Neurological manifestations of hospitalized patients with COVID-19 in Wuhan, China JAMA Neurol. 2020; 77(6): 683–90. doi: 10.1001/jamaneurol.2020.1127.

  7. Sedaghat Z., Karimi N. Guillain Barre syndrome associated with COVID-19 infection: A case report. J Clin Neurosci. 2020; 76: 233–35. doi: 10.1016/j.jocn.2020.04.062.

  8. Sivadon-Tardy V., Orlikowski D., Porcher R. et al. Guillain–Barre syndrome and influenza virus infection. Clin Infect Dis. 2009; 48(1): 48–56. doi: 10.1086/594124.

  9. Polack F.P., Thomas S.J., Kitchin N. et al. C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020; 383(27): 2603–15. doi: 10.1056/NEJMoa2034577.

  10. Randall D.P. Guillain–Barre syndrome and immunizations. Dis Mon. 2010; 56(5): 293–98. doi: 10.1016/j.disamonth.2010.02.009.


About the Autors

Grigory E. Roytberg, MD, professor, head of the Department of therapy, general practice and nuclear medicine, N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia, president of
AO «Meditsina». Address: 125047, Moscow, 10 2nd Tverskoy-Yamskoy Lane. Tel.: +7 (495) 995-00-33. E-mail: contact@medicina.ru. ORCID: 0000-0003-0514-9114
Zhanna V. Dorosh, PhD, associate professor of the Department of therapy, general practice and nuclear medicine,
N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia, Chief physician of AO «Meditsina». Address: 125047, Moscow, 10 2nd Tverskoy-Yamskoy Lane. Tel.: +7 (495) 995-00-33. E-mail: jdorosh@medicina.ru. ORCID: 0000-0001-6078-9654
Natalia V. Kondratova, MD, professor of the Department of therapy, general practice and nuclear medicine,
N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia, inpatient head of AO «Meditsina». Address: 125047, Moscow, 10 2nd Tverskoy-Yamskoy Lane. Tel.: +7 (985) 760-43-96. E-mail: kondratova@medicina.ru. ORCID: 0000-0003-2421-0558
Galina N. Chudinskaya, neurologist of AO «Meditsina». Address: 125047, Moscow, 10 2nd Tverskoy-Yamskoy Lane. Tel.: +7 (985) 760-43-96. E-mail: chudinskaya.g@medicina.ru

Back to Content

Бионика Медиа